**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 81615

**Manuscript Type:** ORIGINAL ARTICLE

***Prospective Study***

**Effectiveness of a new approach to minimally invasive surgery in palliative treatment of patients with distal malignant biliary obstruction**

Susak YM *et al*. An improved technique for BD decompression

Yaroslav M. Susak, Leonid L. Markulan, Serhii M. Lobanov, Roman Y. Palitsya, Mariia P. Rudyk, Larysa M. Skivka

**Yaroslav M. Susak, Serhii M. Lobanov, Leonid L. Markulan,** Department of Surgery with the Course of Emergency and Vascular Surgery, O.O. Bogomolets National Medical University, Kyiv 01601, Ukraine

**Roman Y. Palitsya,** Department of Abdominal Surgery, National Military Medical Clinical Centre “Main Military Clinical Hospital”, Kyiv 01133, Ukraine

**Mariia P. Rudyk, Larysa M. Skivka,** Department of Microbiology and Immunology, Taras Shevchenko National University of Kyiv, Kyiv 01033, Ukraine

**Author contributions:** Susak YM participated in the design of the study and supervised its implementation; Markulan LLparticipated in the study as a chief surgeon and performed surgical procedures; Palitsya RY assisted in surgical procedures; Rudyk MPcontributed to data collection and participated in statistical analysis; Skivka LMparticipated in the design of the study, carried out statistical analysis, and wrote the draft.

**Corresponding author: Mariia P. Rudyk, PhD, Associate Professor,** Department of Microbiology and Immunology, Taras Shevchenko National University of Kyiv, 60 Volodymyrska St, Kyiv 01033, Ukraine. rosiente@gmail.com

**Received:** November 17, 2022

**Revised:** February 5, 2023

**Accepted:** March 3, 2023

**Published online:**

**Abstract**

BACKGROUND

Palliative endoscopic biliary drainage is the primary treatment option for the management of patients with jaundice which results from distal malignant biliary obstruction (DMBO). In this group of patients, decompression of the bile duct (BD) allows for pain reduction, symptom relief, chemotherapy administration, improved quality of life, and increased survival rate. To reduce the unfavorable effects of BD decompression, minimally invasive surgical techniques require continuous improvement.

AIM

To develop a technique for internal-external biliary-jejunal drainage (IEBJD) and assess its effectiveness in comparison to other minimally invasive procedures in the palliative treatment of patients with DMBO.

METHODS

A retrospective analysis of prospectively collected data was performed, which included 134 patients with DMBO who underwent palliative BD decompression. Biliary-jejunal drainage was developed to divert bile from the BD directly into the initial loops of the small intestine to prevent duodeno-biliary reflux. IEBJD was carried out using percutaneous transhepatic access. Percutaneous transhepatic biliary drainage (PTBD), endoscopic retrograde biliary stenting (ERBS), and internal-external transpapillary biliary drainage (IETBD) were used for the treatment of study patients. Endpoints of the study were the clinical success of the procedure, the frequency and nature of complications, and the cumulative survival rate.

RESULTS

There were no significant differences in the frequency of minor complications between the study groups. Significant complications occurred in 5 (17.2%) patients in the IEBJD group, in 16 (64.0%) in the ERBS group, in 9 (47.4%) in the IETBD group, and in 12 (17.4%) in the PTBD group. Cholangitis was the most common severe complication. In the IEBJD group, the course of cholangitis was characterized by a delayed onset and shorter duration as compared to other study groups. The cumulative survival rate of patients who underwent IEBJD was 2.6 times higher in comparison to those of the PTBD and IETBD groups and 20% higher in comparison to that of the ERBS group.

CONCLUSION

IEBJD has advantages over other minimally invasive BD decompression techniques and can be recommended for the palliative treatment of patients with DMBO.

**Key Words:** Distal malignant biliary obstruction; Obstructive jaundice; Bile duct decompression; Palliative endoscopic biliary drainage; Internal-external biliary-jejunal drainage

Susak YM, Markulan LL, Lobanov SM, Palitsya RY, Rudyk MP, Skivka LM. Effectiveness of a new approach to minimally invasive surgery in palliative treatment of patients with distal malignant biliary obstruction. *World J Gastrointest Surg* 2023; In press

**Core Tip:** This study compared the new technique of internal-external biliary-jejunal drainage (IEBJD) for bile duct (BD) decompression in patients with obstructive jaundice with commonly used procedures through a retrospective analysis of prospectively collected data. IEBJD was used to divert bile from the BD directly into the initial loops of the small intestine to prevent duodeno-biliary reflux. The application of IEBJD was associated with a decreased incidence of significant complications, a delayed onset of cholangitis and its shorter duration, as well as an increased cumulative survival rate in patients with distal malignant biliary obstruction as compared to commonly used endoscopic ultrasound-guided retrograde and antegrade techniques and internal-external transpapillary biliary drainage.

**INTRODUCTION**

Patients with jaundice would be ineligible for radical treatment in 70%-85% of cases upon initial examination due to distal malignant biliary obstruction (DMBO)[1,2]. Palliative decompression of the bile ducts (BD) is currently the primary treatment option for the management of patients with obstructive jaundice. This approach allows for pain reduction, symptom relief, and, in some cases, chemotherapy administration[3]. BD decompression not only improves patients’ quality of life but also increases their survival rate[4].

In general, there are two main techniques for performing endoscopic ultrasound-guided minimally invasive BD (EUS-BD) decompression: The EUS-rendezvous approach (retrograde) and the EUS-antegrade technique[5,6], and their combination is also possible[7]. Each method has both advantages and disadvantages.

Percutaneous transhepatic biliary drainage (PTBD) is likely to result in: (1) A significant loss of bile, necessitating the oral administration of bile salts and leaving an implantable port under the skin[6]; and (2) the implantation of metastases along the trajectory of stent placement[8], as well as cholangitis development caused by stent malfunction. Nevertheless, compared to other methods, this one is relatively simple and most affordable. Endoscopic retrograde biliary stenting (ERBS) is considered a method of choice for palliative treatment of patients with DMBO[8,9]. However, it is associated with trauma to the major duodenal papilla (papilla of Vater) and pancreas, which increases the risk of bleeding and pancreatitis development[10] and causes the reflux of duodenal content to the BD[11,12]. It leads to cholangitis development and stent obstruction[13]. The proposed antireflux stents[12,14-16] have not yet found widespread use[17]. In addition, tumor ingrowth and overgrowth, as well as stent occlusion, are potential outcomes[18]. Stents are relatively expensive and difficult to repair and replace[19]. Nevertheless, they provide internal drainage of bile.

Combining the advantages of percutaneous drainage and stenting, internal-external transpapillary biliary drainage (IETBD) involves draining the duodenum while maintaining normal bile outflow. However, there is a high probability of reflux cholangitis. Researchers have polarized opinions about the effectiveness of this approach[9,20-22].

Thus, one of the main reasons for cholangitis being one of the most serious complications of minimally invasive BD decompression techniques, is stent occlusion, which is strongly associated with duodenobiliary reflux. Therefore, avoidance of duodenobiliary reflux is important in preventing stent dysfunction and cholangitis onset[23].

In order to reduce the unfavorable effects of BD decompression in patients with DMBO including cholangitis, the approaches and tools used in minimally invasive procedures, as well as the choice of method, require continuous improvement.

We aimed to develop a technique for internal-external biliary-jejunal drainage (IEBJD) and assess its effectiveness in comparison to other minimally invasive procedures in the palliative treatment of patients with DMBO.

**MATERIALS AND METHODS**

***Study participants***

A prospective, randomized, multicenter study was conducted in three hospitals affiliated with the Department of Surgery with a course of emergency and vascular surgery at O.O. Bogomolets National Medical University (Kyiv): Kyiv City Oleksandrivska Clinical Hospital, Kyiv City Clinical Emergency Hospital, and National Military Medical Clinical Center “Main Military Clinical Hospital”, Kyiv. A total of 134 patients who underwent palliative decompression of the BD due to DMBO between 2017 and 2021 were included in the study. Approval was obtained from the Ethics Committee of O.O. Bogomolets National Medical University (Protocol No. 25-15-65, as of November 28, 2017), and informed consent was given by all participants before the study. The inclusion criteria were: The presence of mechanical jaundice; age over 18 years; the impossibility of radical surgery; and the technical success of the minimally invasive procedure. The exclusion criteria were: Mechanical BD obstruction without jaundice; age less than 18 years; high operative risk [American Society of Anesthetists (ASA) score of 4]; multiple metastatic liver disease; ascites; hemorrhagic diathesis; coagulopathy (international normalized ratio ≥ 1.5); past history of gastrectomy and reconstruction using the Billroth II or Roux-en-Y technique.

Using MS Excel, patients were randomly assigned to four treatment groups in accordance with the BD decompression procedure (Figure 1). The PTBD group included 33 patients; the IETBD group included 30 patients; the ERBS group included 34 patients; and the IEBJD group included 37 patients. However, due to technical difficulties in implementing the planned method, which was subsequently replaced with another one, the number of patients in the groups changed throughout the course of the study. In particular, two patients were not eligible for ERBS (they underwent PTBD); IETBD turned out to be impossible for two patients (they underwent PTBD); during IEBJD, we did not manage to provide drainage distally to the ligament of Treitz in two cases (they underwent IETBD); and it was impossible to insert the drain tube distally to the tumor of the pancreatic head in one patient (he underwent PTBD). All patients who were randomized to the PTBD group were treated using this BD decompression technique.

Thus, the PTBD group included 38 patients, the IETBD group included 30 patients, the ERBS group included 32 patients, and the IEBJD group included 34 patients.

The PTBD and IETBD procedures were carried out using plastic drain tubes of the Pigtail type 9Fr. For ERBS, Partially Covered Nitinol Self-Expandable Metal Stents with a diameter of 8-10 mm were used.

***Methodology of external-internal biliary-jejunal drainage***

IEBJD was used to divert bile from the BD directly into the initial loops of the small intestine to prevent duodeno-biliary reflux and reflux cholangitis. In our study, the IEBJD technique was applied using a newly developed biliary-jejunal drainage system. The drain tube has two groups of lateral openings (proximal and distal), between which it is devoid of openings from the distal border of the tumor to the initial loops of the small intestine[24].

IEBJD was carried out using percutaneous transhepatic access. The end of the drain tube with the distal group of lateral openings is located behind the duodeno-jejunal bend in the initial loops of the jejunum, while the proximal group of lateral openings is located in the dilated BD above the stenosis (Figure 2).

***Endpoints and variables***

Endpoints of the study were the clinical success of the procedure, the frequency and nature of complications from the manipulation, and the cumulative survival rate.

The procedure was considered clinically successful if the serum level of total bilirubin decreased by at least 50% as compared to the baseline value during the first 7 d after manipulation[12].

The Society of Interventional Radiology Clinical Practice Guidelines[25] classified postoperative complications as insignificant or significant.

Significant complications included acute hemobilia, pancreatitis, pneumothorax, sepsis, liver abscess, cholecystitis, biliary peritonitis, bleeding requiring blood transfusion, bile duct rupture, and cholangitis.

The clinical diagnosis of cholangitis was established on the basis of the following criteria: Body temperature above 38.5 °C, leukocyte count > 10 × 109/L, and proportion of neutrophils > 70%[26].

Postoperative pancreatitis was graded as “mild” in cases of the onset or progression of abdominal pain and an elevated serum amylase level three or more times above the reference range within 24 h after the procedure, requiring a minimum of 2-3 d of hospitalization. Pancreatitis was graded as “moderately severe” if the patient required hospitalization for 4-10 d, and as “severe” when the patient required hospitalization for more than 10 d, as well as in cases of necrosis and pseudocysts, indicating the need for percutaneous drainage or open pancreatic debridement[27].

Total bilirubin and α-amylase levels in serum were determined using an automatic biochemical analyzer, Olympus AU-800 (Olympus, Japan). Blood tests were performed using the hematological analyzer Mindray BC-2800 (China).

***Statistical analysis***

Statistical data processing was performed using the statistical package IBMSPPS Statistics 22. To determine whether the observations deviated from the normal curve, the Shapiro-Wilk test was used. Statistical differences were calculated using ANOVA with Tukey’s post-hoc test for multiple comparisons and a two-tailed *t*-test (for normally distributed variables) and non-parametric Mann-Whitney *U* test (for non-normally distributed variables) for single comparisons. A Pearson *χ²* test was used for qualitative data. A cumulative survival rate was estimated by the Kaplan-Meier method using the log-rank test. All differences with a *P* value of < 0.05 were considered statistically significant.

***Ethics statement***

The study protocol was approved by the Ethics Committee of O. O. Bogomolets National Medical University, and informed consent was obtained from all participants before the study.

**RESULTS**

***General characteristics of patients***

The general characteristics of study participants are summarized in Table 1. The anamnesis revealed that mechanical jaundice occurred in patients on an average of 15.2 d ± 0.2 d before the manipulation (from 10 d to 22 d). Patients did not have a statistically significant difference in terms of the average duration of jaundice before surgery.

There were no significant differences in the serum level of total bilirubin between the groups. The mean serum level of total bilirubin was 11.36 mg/dL ± 0.04 mg/dL (3.93-22.78 mg/dL).

There was no statistically significant difference between the study groups in terms of average age, sex ratio, cancer stage, TNM criteria, or etiological factors of stricture.

***Comparative analysis of clinical outcomes of DMBO patients who underwent various minimally invasive procedures***

In the case of PTBD, the technical success was 100%, and it was 94.1% for ERBS, 93.8% for IETBD, and 91.9% for IEBJD (*P* = 0.365).

The clinical success was 94.1% in the IEBJD group, 93.8% in the ERBS group, 86.7% in the IETBD group, and 94.7% in the PTBD group (*P* > 0.582 for all).

Cholangitis, which was diagnosed at admission, subsided within 3-4 d after the procedure.

There were no technical complications (related to the specifics of the manipulation) in any study group. Minor complications occurred both singly and in combination. The groups did not differ statistically in terms of the number of patients with minor complications and their variants (Table 2).

Significant complications occurred in 5 (14.7%) patients in the IEBJD group, in 10 (31.3%) in the ERBS group, in 13 (43.3%) in the IETBD group, and in 8 (21.1%) in the PTBD group (Table 3). In the PTBD and external-internal biliary-jejunal drainage (EIBJD) groups, a significant complication of one type was observed, while in the ERBS and IETBD groups, significant complications of two types were observed in one patient.

The complication rate (*P* = 0.053) did not differ significantly between the groups, but it did differ significantly between the groups where the biliary decompression system connected the lumen of the duodenum to the bile ducts (IETBD and ERBS) and those where it did not (PTBD and IEBJD): 23 (37.1%) *vs* 13 (18.1%), respectively, *P* = 0.013.

The most frequent complication was cholangitis (26 cases, 19.4%). In general, there were no statistically significant differences in the cholangitis rate between the groups (*P* = 0.052). However, when a drain tube or stent was used to connect the lumen of the duodenum to the bile ducts, the frequency of cholangitis was significantly higher than when it was not used: 18 (29.0%) *vs* 8 (11.1%) (*P* = 0.009).

The course of cholangitis in the IEBJD group differed from that in the ERBS and IETBD groups by a longer period before its occurrence after the procedure (*P* < 0.05) and a shorter duration (*P* < 0.05) (Table 4).

The patients who underwent IEBJD had the highest cumulative survival rate [239.3 d, 95% confidence interval (CI): 198.9-279.6 d] when compared to other groups (Figure 3). However, patients in the PTBD (102.0 d, 95%CI: 77.6-128.1 d) and IETBD (94.8 d, 95%CI: 54.1-135.5 d) groups had significantly lower cumulative survival rates (*P* < 0.01) than those in the ERBS group (187.8 d, 95%CI: 153.8-221.9 d).

In comparison to other groups, the mortality risk in the IEBJD group was lower 3, 6, 9, 12, and 15 mo after the start of the procedure (Table 5).

The technique aimed to increase the survival rate of patients with distal block by reducing the risk of duodeno-biliary reflux as well as the frequency and duration of reflux cholangitis. In the IEPTB and ERBS groups, there was a high probability of reflux of duodenal contents into the biliary tract through the drain tube and stent, respectively. Analysis of the impact of cholangitis episodes on the survival rate in these groups confirmed the success of the newly developed technique (Figure 4). The average survival time in patients with cholangitis episodes was 93.9 d (95%CI: 70.4-117.4 d), whereas in patients without cholangitis it was 156.1 d (95%CI: 124.9-191.3 d) (*P* = 0.009); the hazard ratio (HR) was 1.96 (95%CI: 1.02-3.79). However, the cholangitis factor had no effect on the survival rate in patients from the EIBJD group (HR = 1.07, 95%СI: 0.32-3.64).

**DISCUSSION**

Cholangitis is one of the major complications of palliative BD decompression in patients with DMBO. It is recognized as an independent risk factor for liver dysfunction, reduced quality of life, and decreased life expectancy[28].

Cholangitis can develop in cases of gastrointestinal tract infection in patients with an unresectable bilioduodenopancreatic neoplasm due to: (1) Retrograde reflux of intestinal flora during and after the procedure; (2) microbiota dissemination through the external drainage; (3) hematogenous spread of microorganisms; and (4) the contrast reaching the bile ducts. Furthermore, the infection may already be present before the procedure, despite the absence of typical cholangitis manifestations[29,30]. However, duodeno-biliary reflux is the most significant systemic cause of cholangitis. It occurs when the lumen of the duodenum is connected to the lumen of the bile duct, resulting in the disruption or even loss of the barrier function of the sphincter of Oddi[16]. The basal pressure, which is normally created by the sphincter of Oddi (135-202 mm H2O), is higher than that in the duodenum (80-120 mm H2O)[31,32]. Phase contractions of the duodenum are accompanied by an increase in pressure and simultaneous initiation of the sphincter of Oddi contractions, which, in turn, prevent reflux[31]. In contrast, the basal pressure in the common BD is usually in the range of 50-100 mm H2O and does not prevent reflux, especially in the case of connecting the lumen of the bile duct to the lumen of the duodenum[33]. Duodeno-biliary reflux occurs in 100% of patients after ERBS, as demonstrated by duodenography with barium, but it is not always associated with cholangitis[11,12]. After stenting of the BD, 98% of patients show positive bile cultures[34]. Bacteriobilia after ERBS is associated with *Escherichia coli*, *Klebsiella pneumonia*, *Pseudomonas*, *Enterococcus cloacae*, and other microorganisms that are usually resistant to commonly used antibiotics[13]. The high incidence of cholangitis after ERBS has prompted an analysis of a two-step approach to radical treatment of pancreatic head cancer. It has been demonstrated that the number of infectious complications and mortality rate are significantly higher in patients who receive two-stage treatment (BD stenting followed by radical surgery) in comparison to patients who receive one-stage treatment[13]. A meta-analysis including 1435 patients with malignant bile duct obstruction revealed a significantly lower frequency of cholangitis in the case of nasobiliary BD drainage (without duodenobiliary reflux) as compared to ERBS (HR = 0.46, *P* < 0.00001)[35]. In our study, cholangitis occurred in 36.0% of patients in the ERBS group during the follow-up period.

Apparently, favorable conditions for duodeno-biliary reflux and cholangitis also develop after IETBD, as evidenced by the results of the study by Xu *et al*[22], who diagnosed cholangitis in 52.4% of patients with IETBD, which coincides with our observations (31.6%).

Duodeno-biliary reflux after ERBS and IETBD is responsible for the reduced duration of stent patency[21,12,36]. This creates a risk of cholangitis. The presence of the food fibers, bile, bacteria, fibrin, debris, granulation tissue, and inflammatory cells in the occlusive material from removed stents confirms the effect of duodeno-biliary reflux on stent/drainage patency[37]. These sediments are usually infected with Gram-negative bacteria[38]. The biliary stent becomes occluded as a result of biofilm formation caused by bacterial colonization. Biofilm formation begins with the priming of the stent surface by various microbial proteins, followed by microbial adhesion to the stent and the formation of an exopolysaccharide matrix, embedding microbial colonies and other particles into the mature biofilm[39,40]. Over time, this leads to increased bile viscosity, slowed bile flow[41], bile stasis, increased deposition of bile salts[42], and the formation of a brown pigment stone (calcium bilirubinate)[43]. Despite the fact that the stent patency rate is frequently used as an indicator of adverse events following successful placement, we did not compare it between the groups because patients died before stent dysfunction occurred. Namely, in the IETBD and PTBD groups, the stent patency was maintained until the death in 16 (84.2%) and 59 (90.8%) patients, respectively, and the average stent patency duration was mainly determined by the life span and was 69.6 d ± 7.2 d and 84.6 d ± 6.6 d, respectively. At the same time, the average stent patency duration among patients who had drainage obstruction prior to death was 94.3 d ± 3.5 d and 155.2 d ± 20.1 d, respectively (*P* = 0.078). In the IEBJD and ERBS groups, the stent patency was maintained until death in 14 (48.3%) and 12 (48.0%) patients, respectively. The average stent patency duration in these groups was longer than that in the IETBD and PTBD groups: 178.9 d ± 11.5 d and 155.3 d ± 14.3 d, respectively. Among other things, this could be attributed to the longer life expectancy of patients. Nevertheless, in patients who had stent dysfunction before death, the stent patency duration was 204.1 d ± 13.1 d (between 131 d and 275 d) and 168.2 d ± 20.1 d (between 98 d and 292 d), respectively (*P* = 0.047). Although the stent patency duration was longer in the IEBJD group, probably due to the absence of reflux of duodenal content, we decided not to emphasize this fact for the aforementioned reasons. Nevertheless, it should be noted that the cumulative survival rate in the ERBS group with preserved stent patency and cholangitis was 157.1 d (95%CI: 132.1-182.1), while without cholangitis it was 269.6 d (95%CI: 230.3-309.0) (*P* = 0.005). Notably, biliary decompression was not interrupted because of drainage dysfunction in any of the patients and was usually continued for the rest of their lives.

To reduce the incidence of stent-associated cholangitis, stents with anti-reflux valves of various shapes (wine glass-shaped, funnel-shaped, or windsock-shaped) and lengths have been developed[12,16,14,15]. Preliminary data suggest that such stents may be potentially beneficial, although more research is required[17]. Despite the fact that they have patency indices comparable to valveless metal stents[15], they have not been widely used and are prone to dislocation[17]. Kuwatani *et al*[43] noted that, currently, there is no ideal stent with constant patency.

Our study aimed to reduce the incidence of reflux cholangitis. Therefore, we used external-internal drainage to provide bile evacuation into the initial loops of the small intestine, bypassing the duodenum. As a result, the major duodenal papilla is not damaged during the procedure, so the probability of duodeno-biliary reflux is minimal and, in our study, it was not observed. Instead, duodenal contents may enter the bile duct from the outside of the drain.

The possibility of emptying the contents of the small intestine into the choledoch cannot be ruled out, despite the fact that the basal pressure in the intestine is lower[44] or similar to that in the choledoch[45]. In our study, duodeno-biliary reflux was not observed. Furthermore, the pressure in the jejunum does not change (82 mm H2O ± 11 mm H2O) when the balloon located in the duodenum and simulating the passage of the food is inflated (up to 6 mL), in contrast to a significant increase in the pressure in the duodenum (up to 242 mm H2O ± 52 mm H2O) and in the area of duodenojejunal flexure (up to 334 mm H2O ± 48 mm H2O)[45].

We carried out IEBJD on 34 patients with DMBO. A control barium X-ray of the stomach and duodenum did not reveal a reflux of contrast into the BD (Figure 5).

Subcapsular biloma and bleeding, two minor complications that were noted during the manipulation procedure, both subsided on their own without the need for a blood transfusion.

A decrease in the serum level of total bilirubin by more than 50% compared to baseline values was detected in 94.1% of cases. Bile leakage was not observed, unlike in the PTBD group.

In the postoperative period, significant complications occurred in 5 (14.7%) patients in the IEBJD group, in 10 (31.3%) in the ERBS group, in 13 (43.3%) in the IETBD group, and in 8 (21.1%) in the PTBD group. Although there were no significant differences between the groups (*P* = 0.053), the frequency of serious complications was significantly higher in the groups with the connection between the duodenal lumen and the bile ducts than in the groups without it: 23 (37.1 %) *vs* 13 (18.1%) patients, respectively (*P* = 0.013). This can also be referred to cholangitis, which is the most frequent complication: 18 (29.0%) *vs* 8 (11.1%) patients (*P* = 0.009).

The cumulative survival rate was the highest in the IEBJD group, at an average of 239.3 d (95%CI: 198.9-279.6) (*P* < 0.05). Three, six, nine, twelve, and fifteen months after the procedure, patients who underwent IEBJD had a lower mortality risk than those who were treated using other techniques. A lower cholangitis onset rate may account for a higher survival rate in the IEBJD group. It has been shown that cholangitis can be associated with a decrease in life expectancy: 93.9 d (95%CI: 70.4-117.4 d) in the groups with a high risk of duodenal-biliary reflux and reflux cholangitis *vs* 156.1 d (95%CI: 124.9-191.3 d) in the groups without cholangitis (*P* = 0.009) (HR = 1.96, 95%CI: 1.02-3.79). However, cholangitis had no impact on the survival rate in the IEBJD group (HR = 1.07, 95%CI: 0.32-3.64).

In patients with IEJBD, the drain tube is easier to manage in cases of cholangitis symptoms. Antibiotic therapy and drain rehabilitation helped remove cholangitis symptoms within 3-4 d, whereas other methods took 7-14 d.

**CONCLUSION**

Our findings suggest that IEBJD has advantages over other BD decompression techniques in the palliative treatment of patients with DMBO. However, this technique, like other external-internal drainage systems, causes difficulties for the patient since the drain exits the body and requires a drainage bag. Compared to IEBJD, ERBS has advantages in this regard. Moreover, further development of reliable anti-reflux stents would definitely prioritize ERBS use for palliative BD decompression. Nonetheless, IEBJD is currently a cost-effective treatment option, particularly for patients with a short life expectancy. The study has certain limitations, including a relatively small number of patients in the comparison groups. In addition, the study did not include patients with total bilirubin > 20.47 mg/dL and high operative risk (ASA score of 4).

**ARTICLE HIGHLIGHTS**

***Research background***

Patients with distal malignant biliary obstruction (DMBO) may benefit from bile duct (BD) decompression using endoscopic biliary drainage since the procedure reduces pain, relieves symptoms, allows for the administration of chemotherapy, improves quality of life, and increases the survival rate. Cholangitis is one of the main complications of palliative BD decompression in patients with DMBO. Therefore, BD decompression techniques require further improvement to reduce the frequency of cholangitis episodes.

***Research motivation***

Duodeno-biliary reflux (DBR), among others, is regarded as one of the major systemic causes of cholangitis. The aim of the study was to develop a BD drainage technique for bile diversion from the BD directly into the initial loops of the small intestine, preventing DBR and reflux cholangitis.

***Research objectives***

To develop a technique for internal-external biliary-jejunal drainage (IEBJD) and assess its effectiveness in comparison to other minimally invasive procedures.

***Research methods***

In our study, the IEBJD technique was applied using a newly developed biliary-jejunal drainage system. It has two groups of lateral openings (proximal and distal), between which the drainage tube is devoid of openings from the distal border of the tumor to the initial loops of the small intestine. IEBJD was carried out using percutaneous transhepatic access.

***Research results***

The application of the IEBJD technique contributed to a reduction in the incidence of significant postoperative complications, a delayed onset and shorter duration of postoperative cholangitis, and a considerable improvement in the cumulative survival rate of patients with DMBO.

***Research conclusions***

The IEBJD technique prevents DBR and reflux cholangitis and can be recommended for the palliative treatment of patients with DMBO.

***Research perspectives***

The clinical success of the newly developed IEBJD technique in a limited patient group necessitates further evaluation of its efficacy in a larger patient cohort, including those with total bilirubin > 20.47 mg/dL and high operative risk (ASA score of 4).

**ACKNOWLEDGEMENTS**

The authors are very grateful to everyone who took part in this study.

**REFERENCES**

1 **Fernandez Y Viesca M**, Arvanitakis M. Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines. *Clin Exp Gastroenterol* 2019; **12**: 415-432 [PMID: 31807048 DOI: 10.2147/CEG.S195714]

2 **Pereira SP**, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, Almario CV, Halloran C, Lennon AM, Costello E. Early detection of pancreatic cancer. *Lancet Gastroenterol Hepatol* 2020; **5**: 698-710 [PMID: 32135127 DOI: 10.1016/S2468-1253(19)30416-9]

3 **Vandenabeele LAM**, Dhondt E, Geboes KP, Defreyne L. Percutaneous stenting in malignant biliary obstruction caused by metastatic disease: clinical outcome and prediction of survival according to tumor type and further therapeutic options. *Acta Gastroenterol Belg* 2017; **80**: 249-255 [PMID: 29560690]

4 **Walter D**, van Boeckel PG, Groenen MJ, Weusten BL, Witteman BJ, Tan G, Brink MA, Nicolai J, Tan AC, Alderliesten J, Venneman NG, Laleman W, Jansen JM, Bodelier A, Wolters FL, van der Waaij LA, Breumelhof R, Peters FT, Scheffer RC, Steyerberg EW, May AM, Leenders M, Hirdes MM, Vleggaar FP, Siersema PD. Higher quality of life after metal stent placement compared with plastic stent placement for malignant extrahepatic bile duct obstruction: a randomized controlled trial. *Eur J Gastroenterol Hepatol* 2017; **29**: 231-237 [PMID: 27741030 DOI: 10.1097/MEG.0000000000000762]

5 **Pancreatric Section, British Society of Gastroenterology**; Pancreatic Society of Great Britain and Ireland; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; Royal College of Pathologists; Special Interest Group for Gastro-Intestinal Radiology. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. *Gut* 2005; **54 Suppl 5**: v1-16 [PMID: 15888770 DOI: 10.1136/gut.2004.057059]

6 **Riaz A**, Pinkard JP, Salem R, Lewandowski RJ. Percutaneous management of malignant biliary disease. *J Surg Oncol* 2019; **120**: 45-56 [PMID: 30977913 DOI: 10.1002/jso.25471]

7 **Bokemeyer A**, Müller F, Niesert H, Brückner M, Bettenworth D, Nowacki T, Beyna T, Ullerich H, Lenze F. Percutaneous-transhepatic-endoscopic rendezvous procedures are effective and safe in patients with refractory bile duct obstruction. *United European Gastroenterol J* 2019; **7**: 397-404 [PMID: 31019708 DOI: 10.1177/2050640619825949]

8 **Wang L**, Lin N, Xin F, Ke Q, Zeng Y, Liu J. A systematic review of the comparison of the incidence of seeding metastasis between endoscopic biliary drainage and percutaneous transhepatic biliary drainage for resectable malignant biliary obstruction. *World J Surg Oncol* 2019; **17**: 116 [PMID: 31277666 DOI: 10.1186/s12957-019-1656-y]

9 **Lorenz JM**. Management of Malignant Biliary Obstruction. *Semin Intervent Radiol* 2016; **33**: 259-267 [PMID: 27904244 DOI: 10.1055/s-0036-1592330]

10 **Inamdar S**, Slattery E, Bhalla R, Sejpal DV, Trindade AJ. Comparison of Adverse Events for Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction in an Inpatient National Cohort. *JAMA Oncol* 2016; **2**: 112-117 [PMID: 26513013 DOI: 10.1001/jamaoncol.2015.3670]

11 **Misra SP**, Dwivedi M. Reflux of duodenal contents and cholangitis in patients undergoing self-expanding metal stent placement. *Gastrointest Endosc* 2009; **70**: 317-321 [PMID: 19539920 DOI: 10.1016/j.gie.2008.12.054]

12 **Lee YN**, Moon JH, Choi HJ, Choi MH, Lee TH, Cha SW, Cho YD, Choi SY, Lee HK, Park SH. Effectiveness of a newly designed antireflux valve metal stent to reduce duodenobiliary reflux in patients with unresectable distal malignant biliary obstruction: a randomized, controlled pilot study (with videos). *Gastrointest Endosc* 2016; **83**: 404-412 [PMID: 26385187 DOI: 10.1016/j.gie.2015.08.084]

13 **Scheufele F**, Aichinger L, Jäger C, Demir IE, Schorn S, Sargut M, Erkan M, Kleeff J, Friess H, Ceyhan GO. Effect of preoperative biliary drainage on bacterial flora in bile of patients with periampullary cancer. *Br J Surg* 2017; **104**: e182-e188 [PMID: 28121036 DOI: 10.1002/bjs.10450]

14 **Kim DU**, Kwon CI, Kang DH, Ko KH, Hong SP. New antireflux self-expandable metal stent for malignant lower biliary obstruction: in vitro and in vivo preliminary study. *Dig Endosc* 2013; **25**: 60-66 [PMID: 23286258 DOI: 10.1111/j.1443-1661.2012.01324.x]

15 **Hamada T**, Isayama H, Nakai Y, Kogure H, Togawa O, Kawakubo K, Yamamoto N, Ito Y, Sasaki T, Tsujino T, Sasahira N, Hirano K, Tada M, Koike K. Novel antireflux covered metal stent for recurrent occlusion of biliary metal stents: a pilot study. *Dig Endosc* 2014; **26**: 264-269 [PMID: 23621525 DOI: 10.1111/den.12112]

16 **Hu B**, Wang TT, Wu J, Shi ZM, Gao DJ, Pan YM. Antireflux stents to reduce the risk of cholangitis in patients with malignant biliary strictures: a randomized trial. *Endoscopy* 2014; **46**: 120-126 [PMID: 24477367 DOI: 10.1055/s-0034-1364872]

17 **Renno A**, Abdel-Aziz Y, Ahmed T, Alastal Y, Toseef J, Al-Abboodi Y, Nawras A. Antireflux valve metal stent versus conventional self-expandable metal stent in distal malignant biliary obstruction: a systematic review and meta-analysis. *Ann Gastroenterol* 2019; **32**: 605-613 [PMID: 31700238 DOI: 10.20524/aog.2019.0427]

18 **Park CH**, Park SW, Jung JH, Jung ES, Kim JH, Park DH. Comparative Efficacy of Various Stents for Palliation in Patients with Malignant Extrahepatic Biliary Obstruction: A Systematic Review and Network Meta-Analysis. *J Pers Med* 2021; **11** [PMID: 33573288 DOI: 10.3390/jpm11020086]

19 **Shah SFH**, Shah SA, Merchant SA. Investigating temporal patterns of public interest in skin whitening using Google Trends. *Int J Dermatol* 2021; **60**: e160-e161 [PMID: 33372285 DOI: 10.1111/ijd.15380]

20 **Xu C**, Lv PH, Huang XE, Sun L, Wang SX, Wang FA. Internal-external percutaneous transhepatic biliary drainage for patients with malignant obstructive jaundice. *Asian Pac J Cancer Prev* 2014; **15**: 9391-9394 [PMID: 25422230 DOI: 10.7314/apjcp.2014.15.21.9391]

21 **Loew BJ**, Howell DA, Sanders MK, Desilets DJ, Kortan PP, May GR, Shah RJ, Chen YK, Parsons WG, Hawes RH, Cotton PB, Slivka AA, Ahmad J, Lehman GA, Sherman S, Neuhaus H, Schumacher BM. Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. *Gastrointest Endosc* 2009; **70**: 445-453 [PMID: 19482279 DOI: 10.1016/j.gie.2008.11.018]

22 **Xu C**, Huang XE, Wang SX, Lv PH, Sun L, Wang FA. Comparison of infection between internal-external and external percutaneous transhepatic biliary drainage in treating patients with malignant obstructive jaundice. *Asian Pac J Cancer Prev* 2015; **16**: 2543-2546 [PMID: 25824794 DOI: 10.7314/apjcp.2015.16.6.2543]

23 **Wu CH**, Lee MH, Tsou YK, Lin CH, Sung KF, Pan KT, Liu NJ. Risk Factors of Duodenobiliary Reflux-Related Dysfunction of Covered Biliary Metal Stents after Treatment of Duodenal Stricture in Patients with Malignant Biliary and Duodenal Obstruction. *Curr Oncol* 2021; **28**: 3738-3747 [PMID: 34677237 DOI: 10.3390/curroncol28050319]

24 **Susak YM**, Markulan LY, Palitsya RY. [Internal-external biliary-jejunal drainage in the palliative treatment of distal obstructive jaundice]. *Surg East Euro* 2021; **10**: 205-219

25 **Sacks D**, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. *J Vasc Interv Radiol* 2003; **14**: S199-202 [DOI: 10.1097/01.RVI.0000094584.83406.3e]

26 **Yu H**, Yuanyuan S, Guo Z, Xing W, Si T, Guo X, Liu F. Multifactorial analysis of biliary infection after percutaneous transhepatic biliary drainage treatment of malignant biliary obstruction. *J Cancer Res Ther* 2018; **14**: 1503-1508 [PMID: 30589030 DOI: 10.4103/jcrt.JCRT\_256\_18]

27 **Mine T**, Morizane T, Kawaguchi Y, Akashi R, Hanada K, Ito T, Kanno A, Kida M, Miyagawa H, Yamaguchi T, Mayumi T, Takeyama Y, Shimosegawa T. Clinical practice guideline for post-ERCP pancreatitis. *J Gastroenterol* 2017; **52**: 1013-1022 [PMID: 28653082 DOI: 10.1007/s00535-017-1359-5]

28 **Chen M**, Wang L, Wang Y, Wei W, Yao YL, Ling TS, Shen YH, Zou XP. Risk factor analysis of post-ERCP cholangitis: A single-center experience. *Hepatobiliary Pancreat Dis Int* 2018; **17**: 55-58 [PMID: 29428105 DOI: 10.1016/j.hbpd.2018.01.002]

29 **Melzer M**, Toner R, Lacey S, Bettany E, Rait G. Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes. *Postgrad Med J* 2007; **83**: 773-776 [PMID: 18057178 DOI: 10.1136/pgmj.2007.064683]

30 **Kaya M**, Beştaş R, Bacalan F, Bacaksız F, Arslan EG, Kaplan MA. Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients. *World J Gastroenterol* 2012; **18**: 3585-3589 [PMID: 22826624 DOI: 10.3748/wjg.v18.i27.3585]

31 **Behar J**. Physiology and Pathophysiology of the Biliary Tract: The Gallbladder and Sphincter of Oddi-A Review. *ISRN Physiology* 2013; **2013** [DOI: 10.1155/2013/837630]

32 **Gubergrits NB**, Lukashevich GM, Belyaeva NV, Fomenko PG, Borodiy KN, Linevskaya KYu. Duodenal hypertension in practice of gastroenterologist [in Russian]. *Modern Gastroenterology* 2020; **3**: 7-20 [DOI: 10.30978/MG-2020-3-7]

33 **Pitt HA**, Nakeeb A. Bile secretion and pathophysiology of biliary tract obstruction. In:Jarnagin WR. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas. 6th ed. Philadelphia: Elsevier, 2017: 123-132.e1 [DOI: 10.1016/B978-0-323-34062-5.00008-X]

34 **Herzog T**, Belyaev O, Muller CA, Mittelkotter U, Seelig MH, Weyhe D, Felderbauer P, Schlottmann R, Schrader H, Schmidt WE, Uhl W. Bacteribilia after preoperative bile duct stenting: a prospective study. *J Clin Gastroenterol* 2009; **43**: 457-462 [PMID: 19276992 DOI: 10.1097/MCG.0b013e318186b19b]

35 **Lucena GCM**, Barros RA. PRE-OPERATIVE BILIARY DRAINAGE IN THE PERIAMPULLARY NEOPLASIA - A SYSTEMATIC REVIEW. *Arq Bras Cir Dig* 2018; **31**: e1372 [PMID: 29972400 DOI: 10.1590/0102-672020180001e1372]

36 **Leung JW**, Liu YL, Chan RC, Ling TK, Cheng AF. Effects of adherence factors and human bile on bacterial attachment and biliary stent blockage: an in vitro study. *Gastrointest Endosc* 2002; **56**: 72-77 [PMID: 12085038 DOI: 10.1067/mge.2002.125366]

37 **Weickert U**, Venzke T, König J, Janssen J, Remberger K, Greiner L. Why do bilioduodenal plastic stents become occluded? A clinical and pathological investigation on 100 consecutive patients. *Endoscopy* 2001; **33**: 786-790 [PMID: 11558033 DOI: 10.1055/s-2001-16519]

38 **Vaishnavi C**, Samanta J, Kochhar R. Characterization of biofilms in biliary stents and potential factors involved in occlusion. *World J Gastroenterol* 2018; **24**: 112-123 [PMID: 29358888 DOI: 10.3748/wjg.v24.i1.112]

39 **Donelli G**, Guaglianone E, Di Rosa R, Fiocca F, Basoli A. Plastic biliary stent occlusion: factors involved and possible preventive approaches. *Clin Med Res* 2007; **5**: 53-60 [PMID: 17456835 DOI: 10.3121/cmr.2007.683]

40 **Guaglianone E**, Cardines R, Vuotto C, Di Rosa R, Babini V, Mastrantonio P, Donelli G. Microbial biofilms associated with biliary stent clogging. *FEMS Immunol Med Microbiol* 2010; **59**: 410-420 [PMID: 20482630 DOI: 10.1111/j.1574-695X.2010.00686.x]

41 **Sung JY**, Costerton JW, Shaffer EA. Defense system in the biliary tract against bacterial infection. *Dig Dis Sci* 1992; **37**: 689-696 [PMID: 1563308 DOI: 10.1007/BF01296423]

42 **Tohda G**, Dochin M. Management of endoscopic biliary stenting for choledocholithiasis: Evaluation of stent-exchange intervals. *World J Gastrointest Endosc* 2018; **10**: 45-50 [PMID: 29375741 DOI: 10.4253/wjge.v10.i1.45]

43 **Kuwatani M**, Kawakubo K, Sakamoto N. Possible reasons for the regrettable results of patency of an inside stent in endoscopic transpapillary biliary stenting. *Dig Endosc* 2022; **34**: 334-344 [PMID: 33949009 DOI: 10.1111/den.14006]

44 **Vitebsky YD**. [Fundamentals of valvular gastroenterology]. Chelyabinsk: South-Ural, 1986: 126

45 **Shafik A**, Shafik IA, El Sibai O, Shafik AA. Duodeno-jejunal junction dyssynergia: description of a novel syndrome. *World J Gastroenterol* 2007; **13**: 4112-4116 [PMID: 17696232 DOI: 10.3748/wjg.v13.i30.4112]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Committee on Human Rights Related to Research Involving Human Subjects of Kyiv City Clinical Emergency Hospital (Kyiv, Ukraine) (Approval No. 25-15-65).

**Clinical trial registration statement:** This study is registered at https://nddkr.ukrintei.ua/view/rk/67a7ff7c333c5bb067a8c3902353ec74, and the registration identification number is 0121U108878.

**Informed consent statement:** All subjects gave their written informed consent prior to study inclusion.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest to disclose.

**Data sharing statement:** No additional data are available.

**CONSORT 2010 statement:** The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 17, 2022

**First decision:** January 23, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Ukraine

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** dos Santos JS, Brazil; Lin L, China **S-Editor:** Chen YL **L-Editor:** Filipodia Wang TQ **P-Editor:** Chen YL

**Figure Legends**

****

**Figure 1 Patient randomization based on the bile duct decompression techniques used in the study.** AC: Ampullary cancer; CC: Cholangiocarcinoma; ERBS: Endoscopic retrograde biliary stenting; IETBD: Internal-external transpapillary biliary drainage; IJBED: Internal-external biliary-jejunal drainage; MN: Metastatic nodes;PC: Pancreatic cancer; PTBD: Percutaneous transhepatic biliary drainage.

****

**Figure 2** **Layout of external-internal biliary-jejunal drainage placement.**



**Figure 3 Kaplan-Meier cumulative survival curves for patients with distal malignant biliary obstruction who underwent various minimally invasive palliative procedures.** Patients with internal-external biliary-jejunal drainage had a higher survival rate than the other groups (*P* < 0.05). DMBO: Distal malignant biliary obstruction; ERBS: Endoscopic retrograde biliary stenting; IEBJD: Internal-external biliary-jejunal drainage; IETBD: Internal-external transpapillary biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.



**Figure 4 Kaplan-Meier cumulative survival curves for patients with internal-external transpapillary biliary drainage and endoscopic retrograde biliary stenting depending on the presence of cholangitis episodes.** Patients with cholangitis had a lower survival rate compared to those without (*P*< 0.05). ERBS: Endoscopic retrograde biliary stenting; IETBD: Internal-external transpapillary biliary drainage.



**Figure 5 Barium X-ray examination of the stomach and duodenum in a patient 3 mo after external-internal biliary-jejunal drainage for pancreatic head cancer.** Contrast reflux in the bile duct is absent. BD: Bile duct; IEBJD: Internal-external biliary-jejunal drainage.

**Table 1 General characteristics of study participants,*****n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Indicator** | **Total, *n* =134** | **Study group** | ***P* value** |
| **EIBJD, *n* =29** | **ERBS, *n* =25** | **IETBD, *n* =19** | **PTBD, *n* =65** |
| Age in yr, mean ± SD | 64.1 ± 11.6 | 65.8 ± 10.1 | 61.9 ± 12.9 | 62.2 ± 13.0 | 66.0 ± 10.4 | 0.296 |
| Male/female | 69/65 | 19/15 | 17/15 | 14/16 | 19/19 | 0.894 |
| Duration of jaundice in d, mean ± SD | 15.0 ± 2.0 | 14.7 ± 1.5 | 15.5 ± 2.0 | 14.9 ± 2.6 | 14.3 ± 1.1 | 0.250 |
| Total serum bilirubin in mg/dL, mean ± SD | 11.3 ± 4.6 | 12.4 ± 4.5 | 12.3 ± 4.2 | 10.1 ± 5.3 | 10.5 ± 4.2 | 0.092 |
| Cholangitis before the procedure | 19 (14.2) | 6 (17.6) | 4 (12.5) | 4 (13.3) | 5 (13.2) | 0.928 |
| T stage |
|  T2 | 6 (4.6) | 1 (2.9) | 1 (3.1) | 2 (6.7) | 2 (5.3) | 0.985 |
|  T3 | 78 (58.2) | 19 (55.9) | 19 (59.4) | 18 (60.0) | 22 (57.9) |
|  T4 | 50 (37.3) | 14 (41.2) | 12 (37.5) | 10 (33.3) | 14 (36.8) |
| N stage |
|  N0 | 8 (6.7) | 3 (8.8) | 2 (6.3) | 3 (10.0) | 1 (2.6) | 0.922 |
|  N1 | 97 (72.4) | 24 (70.6) | 24 (75.0) | 19 (63.3) | 30 (78.9) |
|  N2 | 11 (8.2) | 3 (8.8) | 2 (6.3) | 4 (13.3) | 2 (5.3) |
|  Nx | 17 (12.7) | 4 (11.8) | 4 (12.5) | 4 (13.3) | 5 (13.2) |
| М stage |
|  М0 | 64 (47.8) | 14(41.2) | 18 (56.3) | 16 (53.3) | 16 (42.1) | 0.858 |
|  М1 | 53 (39.6) | 15 (44.1) | 11 (34.4) | 10 (33.3) | 17 (44.7) |
|  Мх | 17 (12.7) | 5 (14.7) | 3 (9.4) | 4 (13.3) | 5 (13.2) |
| Grade |
|  ІІВ | 4 (3.0) | 1 (2.9) | 1 (3.1) | 2 (6.7) | 0 (0.0) | 0.760 |
|  ІІІ | 47 (35.1) | 12 (35.3) | 13 (40.6) | 10 (33.3) | 12 (31.6) |
|  ІV | 83 (61.9) | 21 (61.8) | 18 (56.3) | 18 (60.0) | 26 (68.4) |
| Tumour etiology |
| Pancreatic cancer | 92 (68.7) | 23 (67.6) | 23 (71.9) | 19 (63.3) | 27 (71.1) | 0.757 |
| Cholangiocarcinoma | 25 (18.7) | 7 (20.6) | 5 (15.6) | 7 (23.3) | 6 (15.8) |
| Ampullary cancer | 14 (10.4) | 2 (5.9) | 3 (9.4) | 4 (13.3) | 5 (13.2) |
| Metastatic nodes | 3 (2.2) | 2 (5.9) | 1 (3.1) | 0 (0.0) | 0 (0.0) |

ERBS: Endoscopic retrograde biliary stenting; IEBJD: Internal-external biliary-jejunal drainage; IETBD: Internal-external transpapillary biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.

**Table 2 Frequency of minor postoperative complications in study groups, *n* (%)**

|  |  |  |
| --- | --- | --- |
| **Complication** | **Study group** | ***P* value** |
| **EIBJD, *n* =34** | **ЕRBS, *n* =32** | **IETBD, *n* =30** | **PTBD, *n* =38** |
| Pain in the drainage area | 6 (17.6) | 5 (15.6) | 7 (23.3) | 7 (18.4) | 0.885 |
| Hyperthermia | 3 (8.8) | - | 2 (6.7) | 3 (7,9) | 0.423 |
| Bile leakage | 1 (2.9) | 2 (6.3) | 1 (3.3) | 2 (5.3) | 0.903 |
| Bleeding | 3 (8.8) | - | 3 (10,0) | 4 (10.5) | 0.325 |
| Subcapsular biloma | 1 (2.9) | 3 (9.4) | 1 (3.3) | 1 (2.6) | 0.498 |
| Shingle pain | 1 (2.9) | - | 1 (3.3) | 2 (5.3) | 0.642 |
| Total | 1 (2.9) | 3 (9.4) | 1 (3.3) | - | 0.223 |

ERBS: Endoscopic retrograde biliary stenting; IEBJD: Internal-external biliary-jejunal drainage; IETBD: Internal-external transpapillary biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.

**Table 3 Frequency and types of significant postoperative complications in study groups,** ***n* (%)**

|  |  |  |
| --- | --- | --- |
| **Indicator** | **Study group** | ***P* value** |
| **EIBJD, *n* =34** | **ЕRBS, *n* =32** | **IETBD, *n* =30** | **PTBD, *n* =38** |
| Patients with complications | 5 (14.7) | 10 (31.3) | 13 (43.3) | 8 (21.1) | 0.053 |
| Number of complications in one patient |
| No | 29 (85.3) | 22 (68.8) | 17 (56.7) | 30 (78.9) | 0.072 |
| One | 5 (14.7) | 7 (21.9) | 10 (33.3) | 8 (21.1) |
| Two | 0 (0.0) | 3 (9.4) | 3 (10.0) | 0 (0.0) |
| Type of complication |
| Cholangitis | 3 (8.8) | 8 (25.0) | 10 (33.3) | 9 (13.2) | 0.052 |
| Pancreatitis |
| No | 32 (94.1) | 28 (87.5) | 27 (90.0) | 38 (100) | 0.121 |
| Mild | 2 (5.9) | 2 (6.3) | 3 (10.0) | 0 (0.0) |
| Moderately severe | 0 (0.0) | 2 (6.3) | 0 (0.0) | 0 (0.0) |
| Cholecystitis | 0 (0.0) | 0 (0.0) | 1 (3.3) | 3 (7.9) | 0.157 |
| Liver abscess | 0 (0.0) | 1 (3.1) | 2 (6.7) | 0 (0.0) | 0.217 |

ERBS: Endoscopic retrograde biliary stenting; IEBJD: Internal-external biliary-jejunal drainage; IETBD: Internal-external transpapillary biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.

**Table 4 Features of cholangitis in study groups**

|  |  |
| --- | --- |
| **Indicator** | **Study group** |
| **EIBJD, *n* =34** | **ЕRBS, *n* =32** | **IETBD, *n* =30** | **PTBD, *n* =38** |
| The time period from the procedure until the cholangitis onset, d | 106.7 ± 38.4a | 75.1 ± 14.9b | 35.3 ± 9.9b | 44.5 ± 9.9b |
| Cholangitis duration, d | 4.7 ± 0.3a | 9.9 ± 0.5b | 7.7 ± 0.6b | 5.3 ± 0.2a |

aDifferent letters indicate significant differences between study groups (Tukey post-hoc test with Bonferroni correction, *P* < 0.05); bDifferent letters indicate significant differences between study groups (Tukey post-hoc test with Bonferroni correction, *P* < 0.05). ERBS: Endoscopic retrograde biliary stenting; IEBJD: Internal-external biliary-jejunal drainage; IETBD: Internal-external transpapillary biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.

**Table 5 Hazard ratios and 95% confidence intervals for the mortality in patients who underwent internal-external biliary-jejunal drainage as compared to other techniques**

|  |  |  |  |
| --- | --- | --- | --- |
| **Observation period in mo** | **PTBD** | **IETBD** | **ERBS** |
| 3 | 0.39; 0.19-0.82, *Р* =0.018 | 0.31; 0.14-0.69, *Р* =0.005 | 0.75; 0.31-1.76, *Р* =0.438 |
| 6 | 0.49; 0.28-0.87, *Р* =0.011 | 0.34; 0.18-0.66, *Р* <0.001 | 0.96; 0.56-1.69, *Р* =0.982 |
| 9 | 0.36; 0.22-0.60, *Р* <0.001 | 0.26; 0.14-0.49, *Р* <0.001 | 0.78; 0.49-1.22, *Р* =0.232 |
| 12 | 0.39; 0.24-0.64, *Р* <0.001 | 0.26; 0.14-0.48, *Р* <0.001 | 0.86; 0.56- 1.32, *Р* =0.507 |
| 15 | 0.38; 0.23-0.62, *Р* <0.001 | 0.30; 0.17-0.54, *Р* <0.001 | 0.77; 0.51-1.16, *Р* =0.078 |

ERBS: Endoscopic retrograde biliary stenting; IETBD: Internal-external transpapillary biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.